Methods: TMR was performed concurrently in 40 patients undergoing major limb amputation as a preemptive measure for symptomatic neuromas and phantom limb phenomena across four centers. Outcomes were assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) and a Numerical Rating Scale and were compared to a cross-section of 727 untreated amputee controls. One-way ANOVA followed by pairwise comparisons of means was conducted between cohorts.
Results: Patients undergoing TMR concurrently with major limb amputation had dramatic improvement in residual limb and phantom limb pain compared to untreated amputee controls across all measures. PROMIS score mean differences for phantom limb pain were 8.1 (CI 5.5–10.7) for Pain Intensity, 8.3 (CI 5.3–11.2) for Pain Behavior and 8.6 (CI 6.0-11.2) for Pain Interference, all p<0.001. Mean differences for residual limb pain were 8.4 (CI 5.4–11.3), 10.1 (CI 6.8–13.5), and 8.9 (CI 5.7–12.1) for PROMIS Pain Intensity, Behavior, and Interference, respectively (all p<.001). Numerical Rating Scale (NRS) data also revealed similar improvements in average residual limb pain (1.98 vs 3.89) and phantom limb pain (2.14 vs 3.96) for concurrent TMR amputees compared to the general amputee population.
Conclusion: Preemptive Targeted Muscle Reinnervation at the time of limb loss should become standard of care for prevention of pathologic phantom and residual limb pain in amputees.